Company: BIVIW
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001520138-25-000144
Chunk: 76

Company: BIOVIE INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 76
---
 “should,” “could,” “may,” “will”
or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements
involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those
expressed or implied by forward-looking statements. These factors include, among others: our research and development activities and distributor
channel; compliance with regulatory requirements; and our ability to satisfy our capital needs Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. 

You are cautioned not to place undue reliance on the
forward-looking statements in this report, which speak only as of the date of this report. Except as may be required by applicable law,
we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking
statements contained in this report as a result of new information or future events or developments, except as required by law. Thus,
you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking
statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the
Securities and Exchange Commission (the “SEC”) that attempt to advise interested parties of the risks, uncertainties and other
factors that may affect our business. 

The following discussion of the Company’s financial
condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere
in this report. 

Management’s Discussion

BioVie Inc. (the “Company” or “we”
or “our”) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including
neurological and neuro-degenerative disorders and liver disease. 

Neurodegenerative Disease Program

The Company acquired the biopharmaceutical assets
of NeurMedix, Inc. (“NeurMedix”) a privately held clinical-stage pharmaceutical company and a related party in June 2021.
The acquired assets included NE3107. In April 2024, the Company announced that the United States Adopted Names Council, and the World
Health Organization International Nonproprietary Names expert committee had approved “bezisterim” as the non-proprietary (generic)
name for NE3107. Bezisterim (NE3107) is an